Sharekhan recommends a buy on Lupin with a target price of Rs 2400, citing strong financial performance and increased EBITDA margin guidance. Lupin, a large-cap pharmaceutical company, reported a net profit of Rs 859.48 crore for the quarter ended September 2024, and its promoters hold a 46.96% stake.